Results 71 to 80 of about 46,300 (164)

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells

BMC Pharmacology and Toxicology, 2017
Background Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGE) production play major roles in progression of diabetic nephropathy. Anti-RAGE effect of peroxisome proliferator-activated receptor-delta (PPARδ) agonists
Jui-Ting Chang, Yao-Jen Liang, Chia-Yu Hsu, Chao-Yi Chen, Po-Jung Chen, Yi-Feng Yang, Yen-Lin Chen, Dee Pei, Jin-Biou Chang, Jyh-Gang Leu   +9 more
doaj   +1 more source

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]

, 2019
Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada, Iwasaki, Mari, Kaunitz, Jonathan D   +2 more
core  

GLP-1 Agonists in Type 1 Diabetes Mellitus: A Review of the Literature [PDF]

, 2016
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like ...
Janzen, Kristin M., Nisly, Sarah A., Steuber, Taylor D.   +2 more
core   +2 more sources

Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study

Obesity Facts
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about
Laura Pazzagli, Ylva Trolle Lagerros
doaj   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S, Chordia, Mahendra D, El Ouarrat, Dalila, Han, Andrew W, Jain, Mohit, Johnson, Andrew MF, Lee, Yun Sok, Mahmood, Nadir A, Ofrecio, Jachelle M, Olefsky, Jerrold M, Pan, Dongfeng, Riopel, Matthew, Ryan, Caitlin N, Watrous, Jeramie D, Wollam, Joshua, Xu, Yong-Jiang, Ying, Wei   +16 more
core   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

The Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao, Elise Chia-Hui Tan, PhD, Lin-Chieh Meng, MS, Yi-Chin Lin, PharmD MS, Ho-Min Chen, MS, Shang-Ting Guan, PharmD, ProfMD PhD Der-Cherng Tarng, PharmD, ProfMD PhD Chih-Yuan Wang, PharmD, Prof Liang-Kung Chen, PharmD   +8 more
doaj   +1 more source

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. [PDF]

, 2014
It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed ...
Akiyama, Taro E, Armando, Aaron M, Bogner-Strauss, Juliane G, Chi, Tyler J, Chung, Heekyung, Cox, Jason M, Di Salvo, Jerry, Evans, Ronald M, Hah, Nasun, Lackey, Denise, Lagakos, William S, McNelis, Joanne, Oh, Da Young, Olefsky, Jerrold M, Pessentheiner, Ariane R, Powels, Mary Ann, Quehenberger, Oswald, Sasik, Roman, Sinz, Christopher, Walenta, Evelyn, Watkins, Steven M   +20 more
core   +1 more source

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]

, 2014
peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core   +1 more source

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier

European Pharmaceutical Journal
While many types of diabetes medications are currently available, orally administered formulations of glucagon-like peptide-1 (GLP-1) receptor agonists have recently been launched. Therefore, gastrointestinal epithelial cells will be increasingly exposed
Takizawa Y., Kato A., Onsui A., Kanatanai S., Ishimura A., Kurita T., Nakajima T.   +6 more
doaj   +1 more source

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice

Pharmaceuticals
Background/Objectives: Type 2 diabetes and weight loss are associated with detrimental skeletal health. Incretin-based therapies (GLP-1 receptor agonists, and dual GIP/GLP-1 receptor agonists) are used clinically to treat diabetes and obesity.
Fang Lv, Xiaoling Cai, Chu Lin, Wenjia Yang, Linong Ji   +4 more
doaj   +1 more source